Salih, M., Al Obaidi, S., Rasheed, H. (2020). Bone Mass Loss in Postmenopausal Women with Early-Stage Breast Cancer (I, II, III) Treated with Aromatase Inhibitors. , 20(4), 350-354. doi: 10.52573/ipmj.2020.170480
Maher Jabbar Salih; Sundus Abd Al Hassan Al Obaidi; Huda Ameen Rasheed. "Bone Mass Loss in Postmenopausal Women with Early-Stage Breast Cancer (I, II, III) Treated with Aromatase Inhibitors". , 20, 4, 2020, 350-354. doi: 10.52573/ipmj.2020.170480
Salih, M., Al Obaidi, S., Rasheed, H. (2020). 'Bone Mass Loss in Postmenopausal Women with Early-Stage Breast Cancer (I, II, III) Treated with Aromatase Inhibitors', , 20(4), pp. 350-354. doi: 10.52573/ipmj.2020.170480
Salih, M., Al Obaidi, S., Rasheed, H. Bone Mass Loss in Postmenopausal Women with Early-Stage Breast Cancer (I, II, III) Treated with Aromatase Inhibitors. , 2020; 20(4): 350-354. doi: 10.52573/ipmj.2020.170480

Bone Mass Loss in Postmenopausal Women with Early-Stage Breast Cancer (I, II, III) Treated with Aromatase Inhibitors

Iraqi Postgraduate Medical Journal
Article 8, Volume 20, Issue 4, 2021, Pages 350-354    PDF (182.63 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2020.170480
Authors
Maher Jabbar Salih1; Sundus Abd Al Hassan Al Obaidi2; Huda Ameen Rasheed3
1Basrah College of Medicine, Basrah, Iraq
2Baghdad Teaching Hospital. Baghdad, Iraq
3Al-Elwiya Maternity Teaching Hospital. Baghdad, Iraq
Abstract
ABSTRACT:
BACKGROUND:
Adjuvant hormonal treatment with aromatase inhibitors for postmenopausal women with early-stage breast cancer is associated with relatively few side effects but it may cause bone mass loss which can be detected with a dual-energy x-ray absorptiometry scan.
AIM:
In this study, we evaluate the skeletal effects of aromatase inhibitors in postmenopausal women with early-stage breast cancer.
PATIENTS AND METHODS:
This is an observational retrospective case-control study enrolled 70 postmenopausal women with               early-stage breast cancer on adjuvant aromatase inhibitors and 70 postmenopausal control women,               the two groups were compared regarding the prevalence and severity of bone mass loss by using                   the DXA scan of their lumbar spine.
RESULTS:
Bone mineral density was significantly lower in breast cancer cases (mean T score was (-2.50 ± 1.01) compared to the control group (mean T score was (-2.12 ± 0.79) with significant (p-value =0.014), also 60%of breast cancer cases were osteoporotic compared to 32% in the control group (p-value =0.005). Based on univariate analysis, breast cancer was associated with 2.79 folds increased probability of osteoporosis
CONCLUSION:
A significant proportion of our breast cancer patients who used aromatase inhibitors were osteoporotic.
 
 
Keywords
DXA; Osteoporosis; aromatase inhibitors
References
  1. Ferlay J SI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
  2. Moore SC, Playdon MC, Sampson JN, et al.  A metabolomics analysis of body mass index and postmenopausal breast cancer risk. J Natl Cancer Inst.  2018; 110:588–97.
  3. Eunice Kennedy Shriver National Institute of Child Healthand Human Development. 2013-06-28. Retrieved 8 March 2015.
  4. Lee.S.J., K.M. Kim, J.K. Brown, et al., Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer, Calcif. Tissue Int. 2015; 97:551–59.
  5. Simpson, E.R., Mahendroo, M.S., Means, G.D. et al, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.Endocr Rev. 1994; 15:342–55.Ann Oncol 24(Suppl 6):vi7–v23. (2013).
  6. Eastell R, Hannon RA, Cuzick J,et al (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination. (ATAC) trial (18233230). J Bone Miner Res. 2006; 21:1215-23.
  7. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol2001; 19:2596-2606[Erratum, J Clin Oncol 2001; 19:3302.]
  8. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial. J Clin     Oncol 2000;18:3758-67.
  9. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12:1527-32.
 

 

 

10. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78-84.

11. Bruning PF, Pit MJ, de Jong-Bakker M, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990; 61 :308–10

12. K G Faulkner, C C Glüer, S Majumdar, P Lang. Noninvasive measurements of bone mass, structure, and strength: current methods and experimental techniques.

13. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report series 843. Geneva: WHO, 1994.

14. Kanis J A, Gluer C C, for the Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 200011192–202.

15. Fraenkel M , Novack V, Liel Y, Koretz M, Siris E, et al. (2013) Association between Bone Mineral Density and Incidence of Breast Cancer. PLoS ONE 8(8): e70980. doi:10.1371/journal.pone.0070980.

16. Hadji P. trial.  Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009; 69:73–82.

17. Kohlmeier, Lynn Kohlmeier (1998 ).osteoporosis– Risk Factors , Screening and Treatment.. Medscape Portals. Retrieved 2008-5-11.

18. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res2006; 21:1215–23.

Statistics
Article View: 285
PDF Download: 164


Journal Management System. Powered by iJournalPro.com